In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy

• Main Authors: Shao Y, Luo W, Guo Q, Li X, Zhang Q, Li J
• Format: Article
• Language: English
• Published: Dove Medical Press 2019-06-01
• Series: Drug Design, Development and Therapy
• Subjects: Acute myeloid leukemia; doxorubicin; gallic acid; multidrug resistance; lipid-polymer hybrid nanoparticles
• Online Access: https://www.dovepress.com/in-vitro-and-in-vivo-effect-of-hyaluronic-acid-modified-doxorubicin-an-peer-reviewed-article-DDDT

Yanping Shao,1 Wenda Luo,1 Qunyi Guo,1 Xiaohong Li,2 Qianqian Zhang,2 Jing Li21Department of Hematology-Oncology, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang 317000, People’s Republic of China; 2Department of Hematology, Hebei Province Hospital of Chinese Medicine, Shijiazhuang, Hebei 050011, People’s Republic of ChinaObjective: To investigate the hyaluronic acid (HA) modified, doxorubicin (DOX) and gallic acid (GA) co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.Methods: We produced a kind of lipid-polymer hybrid nanoparticle (LPHN) with a core-shell structure in which DOX and GA were co-loaded. In vitro and in vivo leukemia therapeutic effects of the HA modified, DOX and GA co-delivered LPHNs (HA-DOX/GA-LPHNs) were evaluated in DOX resistant human HL-60 promyelocytic leukemia cells (HL-60/ADR cells), DOX resistant human K562 chronic myeloid leukemia cells (K562/ADR cells), and HL-60/ADR cells bearing mouse model.Results: The sizes and zeta potentials of HA modified LPHNs were about 160 nm and −40 mV. HA-DOX/GA-LPHNs showed the most prominent cytotoxicity and the best synergistic effect was obtained when DOX/GA ratio was 2/1. In vivo studies revealed that HA-DOX/GA-LPHNs inhibited tumor growth from 956 mm3, to 213 mm,3 with an inhibition rate of 77.7%.Conclusion: In summary, the study showed that HA-DOX/GA-LPHNs can be applied as a promising leukemia therapy system.Keywords: acute myeloid leukemia, doxorubicin, gallic acid, multidrug resistance, lipid-polymer hybrid nanoparticles